XML 23 R10.htm IDEA: XBRL DOCUMENT
v3.25.2

EQUITY SECURITIES PORTFOLIO INVESTMENT | 6 Months Ended
--- | ---
Jun. 30, 2025
Investments, Debt and Equity Securities [Abstract] |
EQUITY SECURITIES PORTFOLIO INVESTMENT | EQUITY SECURITIES Equity securities for the periods presented were comprised of the following:
Security Type | Cost |  | Gross Unrealized Gain |  | Gross Unrealized Loss |  | Fair Value
| (In thousands)
June 30, 2025: |  |  |  |  |  |  |
Equity securities - other common stock | $ | 25,789 |  |  | $ | 7 |  |  | $ | (4,329) |  |  | $ | 21,467 |
Total | $ | 25,789 |  |  | $ | 7 |  |  | $ | (4,329) |  |  | $ | 21,467 |
December 31, 2024: |  |  |  |  |  |  |
Equity securities - other common stock | $ | 24,898 |  |  | $ | 118 |  |  | $ | (1,881) |  |  | $ | 23,135 |
Total | $ | 24,898 |  |  | $ | 118 |  |  | $ | (1,881) |  |  | $ | 23,135 |
Equity Securities Portfolio Investment On April 3, 2020, the Company entered into an Option Agreement with LF Equity Income Fund, which included general terms through which the Company was provided the option to purchase a portfolio of investments in 18 public and private life sciences companies (the “Life Sciences Portfolio”) for an aggregate purchase price of £223.9 million, approximately $277.5 million at the exchange rate on April 3, 2020. For accounting purposes, the total purchase price of the Life Sciences Portfolio was allocated to the individual equity securities based on their individual fair values as of April 3, 2020, in order to establish an appropriate cost basis for each of the acquired securities. The fair values of the public company securities were based on their quoted market price. The fair values of the private company securities were estimated based on recent financing transactions and secondary market transactions and factoring in a discount for the illiquidity of these securities. The total fair value of the remaining Life Sciences Portfolio investment of $25.7 million was included in our consolidated balance sheets as of June 30, 2025 and December 31, 2024. As part of the Company’s acquisition of equity securities in the Life Sciences Portfolio, the Company acquired an equity interest in Arix Bioscience PLC (“Arix”), a public company listed on the London Stock Exchange. On November 1, 2023, the Company, through a wholly owned subsidiary, entered into an agreement (the “Arix Shares Purchase Agreement”) with RTW Biotech Opportunities Ltd. (“RTW Bio”) to sell its shares of Arix to RTW Bio for a purchase price of $57.1 million in aggregate (representing £1.43 per share at an exchange rate of 1.2087 USD/GBP). On January 19, 2024, the Company completed such sale for $57.1 million. Following the completion of the share sale, the Company no longer owns any shares of Arix. The following unrealized and realized gains or losses from our investment in the Life Sciences Portfolio are recorded in the change in fair value of equity securities and gain or loss on sale of equity securities, respectively, in the consolidated statements of operations and comprehensive income (loss):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
| (In thousands)
Change in fair value of equity securities of public companies | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (28,581) |
Gain on sale of equity securities of public companies | — |  |  | — |  |  | — |  |  | 28,581 |
Net realized and unrealized gain | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
As part of the Company’s acquisition of equity securities in the Life Sciences Portfolio, the Company acquired a majority interest in the equity securities of MalinJ1 (63.9%), which were transferred to the Company on December 3, 2020. The acquisition of the MalinJ1 securities was accounted for as an asset acquisition as there was a change of control of MalinJ1 and substantially all of the fair value of the assets acquired was concentrated in a single identifiable asset, an investment in Viamet Pharmaceuticals Holdings, LLC (“Viamet”). As such, the cost basis of the MalinJ1 securities was used to allocate to the Viamet investment, the single identifiable asset, and no goodwill was recognized. The Company through its consolidation of MalinJ1 accounts for the Viamet investment under the equity method as MalinJ1 owns 41.0% of outstanding shares of Viamet. As of June 30, 2025 and December 31, 2024, this investment did not meet the significance thresholds for additional summarized income statement disclosures, as defined by the SEC. D uring the three and six months ended and 2024, there were no earnings on equity investments included in the consolidated statements of operations and comprehensive income (loss). No distributions were received during the three and six months ended June 30, 2025 and 2024.

X
- References No definition available. + Details
Name: | actg_LFEquityIncomeFundPortfolioInvestmentTextBlock
Namespace Prefix: | actg_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration